Evidence map›Paper›PMID 39490950›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2025

Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.

Hannah Bloemen, Alexandra E Livanos, Adrielly Martins, Richard Dean, Ana Catarina Bravo, Arno R Bourgonje, Michael Tankelevich, Jake Herb, Judy Cho, André Anastácio Santos and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Authors' reply.Annals of gastroenterology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hannah BloemenPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Alexandra E LivanosPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: alexandra.livanos@mountsinai.org.
Adrielly MartinsSchiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida.
Richard DeanDivision of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California.
Ana Catarina BravoDivision of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.
Arno R BourgonjePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Michael TankelevichPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Jake HerbThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Judy ChoThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
André Anastácio SantosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Cecília M P RodriguesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Francesca PetraliaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Jean-Frederic ColombelDivision of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Christopher L BowlusDivision of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California.
Thomas SchianoRecanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Joana TorresDivision of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal; Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal.
Cynthia LevySchiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: clevy@med.miami.edu.
Saurabh MehandruPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: saurabh.mehandru@mssm.edu.

Funding

Training Program in Investigative Gastroenterology and HepatologyT32DK131953 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN, Saurabh Mehandru · 2023 to 2026
$1.0M
NIDDK NIH HHS T32 DK131953
6 · The paper itself

Abstract

BACKGROUND &

aimsAnti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with primary sclerosing cholangitis (PSC) and their association with liver disease severity.

methodsFour cohorts of pre-liver transplant patients with PSC were recruited. Patients with inflammatory bowel disease (IBD) and healthy controls (HCs) served as comparators. Total IgG and anti-αvβ6 levels were measured using enzyme-linked immunosorbent assay. Olink inflammation panel was run on a subset of samples. Multivariable linear regression analysis was performed to assess the association between anti-αvβ6 and indices of liver disease severity.

resultsA total of 137 patients with PSC (including 76 with PSC-UC, 33 with PSC-Crohn's disease (CD), and 28 with PSC alone) and 160 controls (including 91 with IBD and 69 HCs) were enrolled. Anti-αvβ6 levels were significantly higher in PSC-UC and PSC-CD compared with PSC alone (P < .0001 and P < .003) and HCs (P < .0001 and P < .0001). However, anti-αvβ6 levels in PSC alone were not increased compared with HCs. In patients with PSC-IBD, anti-αvβ6 levels correlated with markers of liver disease severity, including alkaline phosphatase level (r = 0.32; P = .004), the revised Mayo PSC risk score (r = 0.25; P = .02), and liver stiffness measurement (r = 0.43; P = .008) after adjusting for age, gender, race/ethnicity, and IBD subtype. Additionally, anti-αvβ6 levels were associated with markers of systemic inflammation and tissue remodeling.

conclusionAnti-αvβ6 autoantibodies identify a subset of patients with PSC with concomitant IBD.

Indexed as

Antigens, NeoplasmAutoantibodiesCholangitis, SclerosingInflammatory Bowel DiseasesIntegrinsLiver DiseasesAdultAgedBiomarkersEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedSeverity of Illness IndexAntigens, NeoplasmAutoantibodiesBiomarkersintegrin alphavbeta6IntegrinsAutoantibodiesIntegrin αvβ6Primary Sclerosing CholangitisPrognosisUlcerative Colitis

Identifiers

PMID39490950
PMCPMC12022142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.